Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2021-2027

Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2016-2027)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2016-2021)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027)
2.3 Non-oncology Biopharmaceuticals Industry Dynamic
2.3.1 Non-oncology Biopharmaceuticals Market Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2016-2021)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2016-2021)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2020
3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Type
6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
6.2.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Application
6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
6.3.3 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
6.4 North America Non-oncology Biopharmaceuticals Market Size by Country
6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type
7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
7.2.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application
7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
7.3.3 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type
8.2.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application
8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
8.4.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027)
9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type
9.2.1 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
9.2.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
9.2.3 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application
9.3.1 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
9.3.2 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
9.3.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country
9.4.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
9.4.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type
10.2.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application
10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
10.4.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.5.5 Novo Nordisk Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.8.5 Teva Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Details
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.9.5 Eli Lilly Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Details
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development
11.12 UCB Pharma
11.12.1 UCB Pharma Company Details
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.12.5 UCB Pharma Recent Development
11.13 Amgen
11.13.1 Amgen Company Details
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.13.5 Amgen Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.14.5 AbbVie Recent Development
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.15.5 Takeda Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.16.5 AstraZeneca Recent Development
11.17 Mylan
11.17.1 Mylan Company Details
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.17.5 Mylan Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Details
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.18.5 LEO Pharma Recent Development
11.18 Boehringer Ingelheim
.1 Boehringer Ingelheim Company Details
.2 Boehringer Ingelheim Business Overview
.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
.5 Boehringer Ingelheim Recent Development
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Details
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.20.5 Alexion Pharmaceuticals Recent Development
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Details
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.21.5 Elusys Therapeutics Recent Development
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Details
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.22.5 Swedish Orphan Biovitrum Recent Development
11.23 Biogen
11.23.1 Biogen Company Details
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021)
11.23.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Non-oncology Biopharmaceuticals Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Regions (2016-2021)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2016-2021)
Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020)
Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Non-oncology Biopharmaceuticals Product
Table 64. Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Non-oncology Biopharmaceuticals Product
Table 69. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 74. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Non-oncology Biopharmaceuticals Product
Table 79. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Novo Nordisk Company Details
Table 82. Novo Nordisk Business Overview
Table 83. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 84. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 85. Novo Nordisk Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Non-oncology Biopharmaceuticals Product
Table 89. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 90. Novartis Recent Development
Table 91. Merck Company Details
Table 92. Merck Business Overview
Table 93. Merck Non-oncology Biopharmaceuticals Product
Table 94. Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 95. Merck Recent Development
Table 96. Teva Company Details
Table 97. Teva Business Overview
Table 98. Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 99. Teva Recent Development
Table 100. Eli Lilly Company Details
Table 101. Eli Lilly Business Overview
Table 102. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 103. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 104. Eli Lilly Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 108. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. GlaxoSmithKline Company Details
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Non-oncology Biopharmaceuticals Product
Table 113. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 114. GlaxoSmithKline Recent Development
Table 115. UCB Pharma Company Details
Table 116. UCB Pharma Business Overview
Table 117. UCB Pharma Non-oncology Biopharmaceuticals Product
Table 118. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 119. UCB Pharma Recent Development
Table 120. Amgen Company Details
Table 121. Amgen Business Overview
Table 122. Amgen Non-oncology Biopharmaceuticals Product
Table 123. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 124. Amgen Recent Development
Table 125. AbbVie Company Details
Table 126. AbbVie Business Overview
Table 127. AbbVie Non-oncology Biopharmaceuticals Product
Table 128. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 129. AbbVie Recent Development
Table 130. Takeda Company Details
Table 131. Takeda Business Overview
Table 132. Takeda Non-oncology Biopharmaceuticals Product
Table 133. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 134. Takeda Recent Development
Table 135. AstraZeneca Company Details
Table 136. AstraZeneca Business Overview
Table 137. AstraZeneca Non-oncology Biopharmaceuticals Product
Table 138. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 139. AstraZeneca Recent Development
Table 140. Mylan Company Details
Table 141. Mylan Business Overview
Table 142. Mylan Non-oncology Biopharmaceuticals Product
Table 143. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 144. Mylan Recent Development
Table 145. LEO Pharma Company Details
Table 146. LEO Pharma Business Overview
Table 147. LEO Pharma Non-oncology Biopharmaceuticals Product
Table 148. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 149. LEO Pharma Recent Development
Table 150. Boehringer Ingelheim Company Details
Table 151. Boehringer Ingelheim Business Overview
Table 152. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product
Table 153. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 154. Boehringer Ingelheim Recent Development
Table 155. Alexion Pharmaceuticals Company Details
Table 156. Alexion Pharmaceuticals Business Overview
Table 157. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product
Table 158. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 159. Alexion Pharmaceuticals Recent Development
Table 160. Elusys Therapeutics Company Details
Table 161. Elusys Therapeutics Business Overview
Table 162. Elusys Therapeutics Non-oncology Biopharmaceuticals Product
Table 163. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 164. Elusys Therapeutics Recent Development
Table 165. Swedish Orphan Biovitrum Company Details
Table 166. Swedish Orphan Biovitrum Business Overview
Table 167. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product
Table 168. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 169. Swedish Orphan Biovitrum Recent Development
Table 170. Biogen Company Details
Table 171. Biogen Business Overview
Table 172. Biogen Non-oncology Biopharmaceuticals Product
Table 173. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 174. Biogen Recent Development
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2020 VS 2027
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2027
Figure 5. Immunology Case Studies
Figure 6. Endocrinology Case Studies
Figure 7. Others Case Studies
Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Regions: 2020 VS 2027
Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027)
Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Players in 2020
Figure 14. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2020
Figure 16. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027)
Figure 18. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 21. North America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 22. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Type (2016-2027)
Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Application (2016-2027)
Figure 27. Europe Non-oncology Biopharmaceuticals Market Share by Country (2016-2027)
Figure 28. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Non-oncology Biopharmaceuticals

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs